Showing results (571-580 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|May 16, 2019
The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982-2012: a cross-sectional population-based studyYuna He, Yanping Li, Xiaoguang Yang, et al.
The Lancet. Diabetes & Endocrinology|January 12, 2020
Approach to patients with hypophosphataemiaPablo Florenzano, Cristiana Cipriani, Kelly L Roszko, et al.
The Lancet. Diabetes & Endocrinology|May 16, 2022
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional studyAnn V Schwartz, Jye-Yu C Backlund, Ian H de Boer, et al.
The Lancet. Diabetes & Endocrinology|February 5, 2018
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trialRichard E Pratley, Vanita R Aroda, Ildiko Lingvay, et al.
The Lancet. Diabetes & Endocrinology|February 28, 2018
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trialBernhard Ludvik, Juan P Frías, Francisco J Tinahones, et al.
The Lancet. Diabetes & Endocrinology|June 25, 2022
Diagnosis of thyroid nodulesErik K Alexander, Edmund S Cibas
The Lancet. Diabetes & Endocrinology|July 5, 2022
Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillanceRoss Hamblin, Ashley Vardon, Josephine Akpalu, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2020
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trialNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
The Lancet. Diabetes & Endocrinology|June 6, 2014
Treatment of hypopituitarism in patients receiving antiepileptic drugsRosa Maria Paragliola, Alessandro Prete, Peter W Kaplan, et al.
Pageof 93